UPDATED: Alkermes advances monthly schizophrenia drug; Impax/GSK submit NDA for Parkinson's drug;

> Alkermes ($ALKS) has begun testing a once-monthly version of aripiprazole in a Phase III clinical trial that will ultimately include 690 schizophrenia patients. Release

>Impax Pharmaceuticals ($IPXL) has submitted a new drug application to the FDA for IPX066, a Parkinson's disease treatment being developed with GlaxoSmithKline ($GSK) with an extended release capsule formulation of carbidopa-levodop. Release

> Thanks to positive results from a Phase Ib clinical study, Radius Health will advance to a Phase II proof-of-concept trial for its BA058 microneedle patch as a transdermal treatment of osteoporosis. Release

> IntelGenx will let Par Pharmaceutical use its proprietary oral drug delivery tech for a new undisclosed product to be sold in the U.S., in return for upfront and milestone payments and a percentage of the profits. Release

> GeNO has obtained two new patents for nitric oxide drug delivery technology, adding to seven already in place. Release

> Pulmatrix said its iSPERSE inhaled dry powder platform worked better than conventional inhaled delivery formulations in additional clinical testing against GlaxoSmithKline's Advair Discus bronchodilator, when formulated with the same lung treatment. Release

[CLARIFICATION: We want to make clear that Alkermes does not own Abilify, which is jointly marketed by Otsuka and Bristol-Myers Squibb.]

Suggested Articles

The new digital Abilify is a breakthrough for Proteus Digital Health and its patient-tracking products, but not so much for Abilify's maker, Otsuka.

Adamis Pharmaceuticals' EpiPen contender Symjepi, which was rejected last year before the EpiPen havoc, won approval from the FDA.

Researchers in the U.K. have developed a technique to better predict results in liver cancer when drug-laden polymer beads are used to deliver medicines.